Abstract
Thalidomide and the analogues lenalidomide (CC-5013, Revlimid®) and CC-4047 (Actimid®) belong to the family of immunomodulatory drugs (IMiDs). These agents have anti-angiogenic properties, modulate TNFα and IL-12 secretion, co-stimulate T cells, increase NK cell toxicity and have direct anti-tumour effects. These characteristics have made of them promising drugs for treatment of relapsed, refractory and newly diagnosed MM. It seems that lenalidomide and CC-4047 are more powerful in inhibiting TNFα and have, except for myelosuppression, less side effects than Thal. Combination of IMiDs with dexamethasone, bortezomib and with chemotherapeutic agents are tested in numerous trials, which will help in determining the optimal combination and administration schedule of different molecules to take advantage of non-overlapping toxicities and synergisms between those agents.
Keywords: immunomodulatory drugs, multiple myeloma, thalidomide, CC-5013, lenalidomide, CC-4047
Current Pharmaceutical Biotechnology
Title: Immunomodulatory Drugs as a Therapy for Multiple Myeloma
Volume: 7 Issue: 6
Author(s): H. De Raeve and K. Vanderkerken
Affiliation:
Keywords: immunomodulatory drugs, multiple myeloma, thalidomide, CC-5013, lenalidomide, CC-4047
Abstract: Thalidomide and the analogues lenalidomide (CC-5013, Revlimid®) and CC-4047 (Actimid®) belong to the family of immunomodulatory drugs (IMiDs). These agents have anti-angiogenic properties, modulate TNFα and IL-12 secretion, co-stimulate T cells, increase NK cell toxicity and have direct anti-tumour effects. These characteristics have made of them promising drugs for treatment of relapsed, refractory and newly diagnosed MM. It seems that lenalidomide and CC-4047 are more powerful in inhibiting TNFα and have, except for myelosuppression, less side effects than Thal. Combination of IMiDs with dexamethasone, bortezomib and with chemotherapeutic agents are tested in numerous trials, which will help in determining the optimal combination and administration schedule of different molecules to take advantage of non-overlapping toxicities and synergisms between those agents.
Export Options
About this article
Cite this article as:
De Raeve H. and Vanderkerken K., Immunomodulatory Drugs as a Therapy for Multiple Myeloma, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116847
DOI https://dx.doi.org/10.2174/138920106779116847 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Advances and Patents about Medical Surgical Operation Skull Grinding Equipment
Recent Patents on Engineering Uric Acid and Oxidative Stress
Current Pharmaceutical Design Adiponectin, Structure, Function and Pathophysiological Implications in Non-Alcoholic Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Furanodienone: An Emerging Bioactive Furanosesquiterpenoid
Current Organic Chemistry Pharmacology of the Human Saphenous Vein
Current Vascular Pharmacology Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery
Current Medicinal Chemistry Synthesis of Benzo[d]imidazo[2,1-b]thiazole-Propenone Conjugates as Cytotoxic and Apoptotic Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Medicinal Chemistry of Potassium Channel Modulators: An Update of Recent Progress (2011-2017)
Current Medicinal Chemistry Ferulic Acid and Alzheimer’s Disease: Promises and Pitfalls
Mini-Reviews in Medicinal Chemistry Neuronal Histamine and its Receptors: Implication of the Pharmacological Treatment of Obesity
Current Medicinal Chemistry Role of CD38 in Airway Function
Current Respiratory Medicine Reviews A Review of Pharmacological and Phytochemical Studies on Convolvulaceae Species <i>Rivea</i> and <i>Ipomea</i>
Current Traditional Medicine Vasculopathy in Hyperthyroid Rats and Targets for Drug Effects
Vascular Disease Prevention (Discontinued) Triple Treatment with Octreotide, Galanin and Serotonin is a Promising Therapy for Colorectal Cancer
Current Pharmaceutical Design Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Superoxide Dismutase in Redox Biology: The Roles of Superoxide and Hydrogen Peroxide
Anti-Cancer Agents in Medicinal Chemistry Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Polyphenols and Cardiovascular Disease: A Critical Summary of the Evidence
Mini-Reviews in Medicinal Chemistry